A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
Solid Tumor, melanoma, HR+ breast cancer, ovarian cancer, prostate cancer, colorectal cancer, urothelial carcinoma, adoptive cell therapy, neoantigen, T cell receptor, T lymphocyte, TCR-engineered T cells, personalized cell therapy, cell therapy, immunotherapy, gene therapy, PD-1, non-small cell lung cancer, head and neck squamous carcinoma, HER2 negative breast cancer, triple negative breast cancer, IL-2, Neoplasms, Aldesleukin, Nivolumab, Interleukin-2, NeoTCR-P1 adoptive cell therapy, NeoTCR-P1, NeoTCR-P1 plus nivolumab, NeoTCR-P1 plus IL-2
Lead Scientist at University of California Health
- David Oh (ucsf)
I am a physician-scientist focused on developing novel immunotherapies with enhanced activity and reduced toxicity, for patients with solid cancers. Clinically, I see patients in the Cancer Immunotherapy Program where I lead numerous early phase trials, with a particular focus on adoptive cell therapies for solid tumors (CAR-T and TCR).
- currently not accepting new patients, but might later
- Start Date
- Completion Date
- PACT Pharma, Inc.
- Phase 1 research study
- Study Type
- About 21 people participating
- Last Updated